ADVERTISEMENT

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

Risk Analysis

Risk Analysis

Volume 26 Issue 6, Pages 1423 - 1440

Published Online: 10 Nov 2006

© 2010 Society for Risk Analysis



< Previous Abstract  |  Next Abstract >

Save Article to My Profile      Download Citation      Request Permissions

Abstract |  References  |  Full Text: HTML, PDF (Size: 358K)  | Related Articles | Citation Tracking

Retrospective Cost-Effectiveness Analyses for Polio Vaccination in the United States
Kimberly M. Thompson 1,2* and Radboud J. Duintjer Tebbens 1,3
  1 Kids Risk Project, Harvard School of Public Health, Harvard University, MA, USA.   2 Sloan School of Management, Massachusetts Institute of Technology, MA, USA.   3 Delft University of Technology, Department of Mathematics, The Netherlands.
  *Address correspondence to Kimberly M. Thompson, Kids Risk Project, Harvard School of Public Health, 677 Huntington Avenue, 3rd Floor, Boston, MA 02115, USA; tel: (617) 432-4285; kimt@hsph.harvard.edu.
Copyright 2006 Society for Risk Analysis
KEYWORDS
Cost-benefit analysis • cost-effectiveness analysis • polio • vaccination

ABSTRACT

The history of polio vaccination in the United States spans 50 years and includes different phases of the disease, multiple vaccines, and a sustained significant commitment of resources. We estimated cost-effectiveness ratios and assessed the net benefits of polio vaccination applicable at various points in time from the societal perspective and we discounted these back to appropriate points in time. We reconstructed vaccine price data from available sources and used these to retrospectively estimate the total costs of the U.S. historical polio vaccination strategies (all costs reported in year 2002 dollars). We estimate that the United States invested approximately $35 billion (1955 net present value, discount rate of 3%) in polio vaccines between 1955 and 2005 and will invest approximately $1.4 billion (1955 net present value, or $6.3 billion in 2006 net present value) between 2006 and 2015 assuming a policy of continued use of inactivated poliovirus vaccine (IPV) for routine vaccination. The historical and future investments translate into over 1.7 billion vaccinations that prevent approximately 1.1 million cases of paralytic polio and over 160,000 deaths (1955 net present values of approximately 480,000 cases and 73,000 deaths). Due to treatment cost savings, the investment implies net benefits of approximately $180 billion (1955 net present value), even without incorporating the intangible costs of suffering and death and of averted fear. Retrospectively, the U.S. investment in polio vaccination represents a highly valuable, cost-saving public health program. Observed changes in the cost-effectiveness ratio estimates over time suggest the need for living economic models for interventions that appropriately change with time. This article also demonstrates that estimates of cost-effectiveness ratios at any single time point may fail to adequately consider the context of the investment made to date and the importance of population and other dynamics, and shows the importance of dynamic modeling.


DIGITAL OBJECT IDENTIFIER (DOI)
10.1111/j.1539-6924.2006.00831.x About DOI

Related Articles

  • Find other articles like this in Wiley InterScience
  • Find articles in Wiley InterScience written by any of the authors

Wiley InterScience is a member of CrossRef.

Cross Ref Member


Hot Topic
RISK

Risk Analysis


CLICK HERE to read the sample issue.

Business & Management